Aurinia Pharmaceuticals (AUPH) stock is soaring 5.08% in pre-market trading on Friday, following the release of impressive second-quarter 2025 financial results and an optimistic outlook for the full year. The biopharmaceutical company, focused on developing therapies for autoimmune diseases, has significantly outperformed market expectations.

The company reported a 22% year-over-year increase in revenue, reaching $70.0 million and beating analyst estimates by $6.2 million. Earnings per share (EPS) showed remarkable growth, jumping from $0.01 in the previous year to $0.16, surpassing the analyst consensus of $0.15. This substantial improvement in profitability can be attributed to higher sales and effective cost management following a restructuring initiative in late 2024.

Buoyed by the strong performance, Aurinia's management raised its full-year 2025 guidance. The company now projects total revenue between $260 million and $270 million, up from the previous forecast of $250 million to $260 million. This upward revision signals management's confidence in the continued success of LUPKYNIS, Aurinia's primary commercial product for lupus nephritis. Adding to the positive sentiment, RBC Capital Markets raised its price target for Aurinia from $8 to $9, maintaining an Outperform rating. The combination of strong financial results, raised guidance, and favorable analyst views appears to be driving investor enthusiasm, resulting in the significant pre-market stock price surge.